DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

Karen Krasney, EVP and General Counsel of Capricor Therapeutics, exercised and sold 25,000 stock options for approximately $793,000 on May 1, 2026, reducing her direct equity position by 45%. The sale was executed under a pre-scheduled 10b5-1 trading plan established in December 2025, indicating a diversification move rather than a loss of confidence. Krasney retains 30,547 common shares and 56,261 unexercised options, maintaining material exposure to the company.

Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for its cell therapy candidate deramiocel, causing its stock to surge dramatically. Martin Shkreli, who had previously predicted the trial's failure, criticized the data and claimed the company changed its primary endpoint.

Capricor Therapeutics met with the FDA to discuss regulatory approval for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA provided clarity on the approval process and showed flexibility in reviewing trial data, causing the stock to surge.

Capricor Therapeutics received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, causing a significant stock price drop and triggering a potential securities class action lawsuit.

A class action lawsuit has been filed against Capricor Therapeutics alleging false and misleading statements about the safety and efficacy of its Phase 2 HOPE-2 trial for deramiocel, with potential regulatory approval challenges.

Rosen Law Firm is pursuing a securities class action lawsuit against Therapeutics for allegedly providing misleading statements about its cell therapy drug deramiocel and its Phase 2 trial data, potentially causing investor damages.

Bragar Eagel & Squire filed a class action lawsuit against Capricor Therapeutics regarding misleading statements about its cell therapy drug deramiocel. The FDA denied the Biologics License Application, causing the stock price to drop significantly.

Rosen Law Firm alerts Capricor Therapeutics investors about a September 15, 2025 deadline for a securities class action lawsuit related to allegedly misleading statements about a cell therapy drug's safety and efficacy data.

A class action lawsuit has been filed against Capricor Therapeutics alleging false and misleading statements about the safety and efficacy of its Phase 2 HOPE-2 trial for deramiocel, with potential regulatory approval challenges.

Rosen Law Firm alerts Capricor Therapeutics investors about a securities class action lawsuit regarding potentially misleading statements about deramiocel's safety and efficacy data during the period of October 9, 2024 to July 10, 2025.

Capricor Therapeutics faces a class action lawsuit alleging false statements about its drug candidate's FDA approval progress, with shareholders encouraged to join a potential recovery effort.